The Scarlett Letter

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

The Scarlett Letter

Post by biopearl123 » Mon Nov 30, 2020 8:42 pm

Every year there is a run up in stock price before ASH. Then a sell off. This year looks different. It's like the financial analysts haven't read the abstracts. Its like big Pharma haven't read the abstracts. Geron is presenting amazing data to support a drug that changes the natural history of diseases. Evidence that Imetelstat prolongs life and inhibits the cancer stem cell. Dr. Ma has shown a direct effect of Imetelstat showing the ability of the drug to stop progression of chronic myelocytic leukemia to blast crisis (AACR data) and death of the myelofibrosis stem cell (ASH presentation) while sparing the normal hematopoietic stem cell. Hundreds of blood transfusion have been avoided just with the small studies already done. Definite suppression of malignant mutations have been demonstrated. The stock is down because it carries a "Scarlett Letter"--and its a "J". Because J and J said no, the stock has had a reputation to rebuild. Fortunately for us, J and J made its decision on the basis of very incomplete data. It's an unfair situation in the face of amazing progress in presenting a drug with a completely new MOA and one that strikes at the actual root of a problem. But it can't get no respect because it was jilted by Janssen. The market appears to have a long memory but some partner (and us), will benefit as a result from this under the radar drug. The Geron team under the guidance of Dr. Rizo doesn't get much better. And do not underestimate the power of an association with the Catriona Jamison lab in San Diego. If anyone knows of a drug that can selectively attach the malignant clone in MPDs please post the info. More after ASH. Best Wishes, stay healthy, bp

biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Re: The Scarlett Letter

Post by biopearl123 » Mon Nov 30, 2020 8:45 pm

I suppose that should read "and we". bp

cheng_ho
Posts: 202
Joined: Sun Apr 03, 2016 11:27 pm

Re: The Scarlett Letter

Post by cheng_ho » Mon Nov 30, 2020 8:47 pm

Don't forget the recent large dilution at $1.30, and the fact that Scarlett is sitting on yet another ATM issue. If Geron had some good news (e.g., finally completing enrollment of a trial), Scarlett stands ready to crush the stock price yet again. The market has been burned by Geron dozens of times since 2000's collapse, obviously they are averse to losing money there again.... as are all possible pharma partners. No one wants to follow MRK or JNJ's example and lose tens of millions in Geron with no result.

LWS
Posts: 581
Joined: Thu Jul 14, 2016 2:00 am

Re: The Scarlett Letter

Post by LWS » Tue Dec 01, 2020 4:31 pm

(IMO) JNJ/Janssen still has an eye on Imetelstat. Dr. Rizo and others that spent time at Janssen are not at Geron by accident. Imetelstat has had many medical successes, with combination potential yet to be explored.

Post Reply